DLL3 and small cell lung carcinoma: Conversely, expression of DLL3, the target of multiple agents currently under clinical investigation in SCLC (ADCs, T cell engagers, CAR–T cells) (36, 37) was restricted to NEPC tumors (Fig. 1I) and showed strong concordance with NEPC TFs (CCC = 0.9, 95% CI 0.87 to 0.93) (SI Appendix, Fig. S1F).